Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen Oral Immunotherapy

Trial Profile

Phase 2 Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen Oral Immunotherapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AR 101 (Primary)
  • Indications Peanut hypersensitivity
  • Focus Registrational; Therapeutic Use
  • Acronyms ARC001
  • Sponsors Allergen Research Corporation
  • Most Recent Events

    • 31 Jan 2020 According to an Aimmune Therapeutics media release, in connection with the FDA approval announcement the company will host a conference call and webcast today.
    • 31 Jan 2020 According to an Aimmune Therapeutics media release, the the U.S. Food and Drug Administration (FDA) approved PALFORZIA(AR-101) for treatment of peanut allergy in children and adolescents aged 4 - 17 years. The Biologics License Application (BLA) included efficacy and safety data from seven clinical studies, including the pivotal Phase 3 PALISADE and RAMSES clinical trials. In addition, data from ARC001, ARC002, ARC004, ARC008 and ARC011 were included.
    • 31 Oct 2017 According to an Aimmune therapeutics media release, results from this trial have been published in The Journal of Allergy and Clinical Immunology.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top